Platelet-Rich Plasma (PRP) Therapy for Knee Osteoarthritis

Introduction

As a clinician and researcher committed to integrative musculoskeletal care, I have seen a profound shift in how we approach degenerative joint disease—particularly symptomatic knee osteoarthritis (OA). Today, the way we treat degenerative joint disease, especially knee osteoarthritis (OA), is changing because of new research and well-planned studies that show how therapies like platelet-rich plasma (PRP) compare to traditional treatments like corticosteroid and hyaluronic acid (HA) injections. In this educational post, I present a comprehensive, first-person examination of PRP therapy—its biology, clinical applications, mechanisms, protocol optimization, patient selection, and outcomes—with an emphasis on current findings from leading researchers and methodologically rigorous investigations. My goal is to illuminate not only what PRP does, but also why and how it may confer symptomatic relief and chondroprotective effects in knee OA when applied thoughtfully, ethically, and in alignment with the highest standards of clinical practice.

We start by describing knee osteoarthritis as a complicated condition that involves the gradual breakdown of cartilage, inflammation in the joint lining, changes in the bone beneath the cartilage, wear and tear of the meniscus, and Understanding these biological and mechanical contributors is crucial because targeted interventions should address the underlying physiology rather than only dampen pain signals. PRP, which is made from a patient’s own blood using centrifugation, focuses on platelets and various helpful substances—like growth factors, cytokines, and extracellular vesicles—that can help reduce inflammation, promote cell growth in cartilage, affect joint lining cells, and possibly slow down the breakdown of joint tissues.

Across the literature, PRP is frequently compared to intra-articular corticosteroids and HA. While steroids can reliably reduce pain in the short term through anti-inflammatory actions, recurrent use may be associated with cartilage loss and diminishing returns. HA may improve joint lubrication and viscoelastic properties, yet response variability remains high, and benefits often attenuate over time. In contrast, the idea behind PRP is to help the body heal itself by changing the joint environment from one that causes inflammation to one that promotes repair. Many studies have shown that using PRP can lead to significant improvements in pain and function for people with knee OA, and new information suggests that the effects can vary based on the amount used, its makeup, and how it’s applied, which means careful consideration

This post explains how PRP works, including how platelets are activated, the roles of various growth factors like TGF-β, PDGF, VEGF, IGF-1, HGF, PF4, and I talk about the range from leukocyte-poor PRP (LP-PRP) to leukocyte-rich PRP (LR-PRP), explaining why LP-PRP is usually preferred for treating knee We will examine the following preparation variables—centrifugation protocols, platelet concentration targets, avoidance of red cell contamination, activation techniques (calcium chloride versus endogenous activation), and timing across serial injections—to clarify how specific choices can shape clinical outcomes.

I will also review patient selection, contraindications, co-management strategies, multimodal care (including rehabilitation and load management), and long-term follow-up. We will look at how well patients do using trusted measures (WOMAC, KOOS, VAS), along with imaging tests and new markers that show joint health By bringing together the latest research from top experts who use modern, evidence-based methods—like randomized controlled trials, systematic reviews, network meta-analyses, and standardized reporting—we can create a clear plan for including PRP in complete osteoarthritis treatment while recognizing the uncertainties and areas that need more research.

My experience mirrors the literature: in selected patients with symptomatic knee OA, PRP is often a highly effective modality, particularly when compared head-to-head with corticosteroids or HA monotherapy and implemented with protocol rigor. Notably, recent research points to potential chondroprotective properties of PRP, hinting at disease-modifying potential rather than mere symptomatic relief. While no single therapy is universally effective, PRP continues to demonstrate promising results, and with ongoing scientific refinement, it is poised to play a major role in the future of OA management.

Evidence-Based Insights into Platelet-Rich Plasma for Knee Osteoarthritis

Bold Overview: Why I Use PRP in Symptomatic Knee OA

In my practice as a DC and FNP-APRN, I have integrated platelet-rich plasma (PRP) as a core option for patients with symptomatic knee osteoarthritis who seek an approach targeting inflammation, biomechanics, and tissue homeostasis. Patients frequently come to me after trials of NSAIDs, physical therapy, bracing, and injections such as corticosteroids or hyaluronic acid (HA). While these have roles, many patients experience limited durability or adverse profiles with repeated steroid injections. With PRP, I consistently observe sustained improvements in pain, stiffness, and function—especially in patients with mild-to-moderate OA—when protocols are optimized and rehabilitation is properly aligned.

Two pillars drive my confidence in PRP.

• First, the biological plausibility is grounded in platelet-derived growth factors and cytokine-modulating effects.
• Secondly, the clinical evidence, which includes randomized controlled trials and meta-analyses, compares PRP to HA and corticosteroids, demonstrating superior or longer-lasting outcomes in numerous cohorts.

Besides reducing symptoms, the most interesting new research suggests that PRP may help protect cartilage and possibly slow down damage to it. While we must interpret these findings conservatively, they have meaningful implications for treatment strategies and patient outcomes in managing knee osteoarthritis.

Understanding Knee Osteoarthritis: Pathophysiology and Clinical Phenotypes

Knee OA is not a simple “wear-and-tear” condition; it is a multifactorial joint disease marked by:

• Catabolic enzymes like MMP-13, ADAMTS-4/5, and pro-inflammatory cytokines like IL-1β, TNF-α, and IL-6 cause the breakdown of the cartilage matrix.
• Synovial inflammation (synovitis) that amplifies nociception through NGF and sensitizes joint afferents.
• Changes in the bone just below the cartilage, including damage to the bone marrow, imbalances in bone-building and bone-breaking cells, and tiny cracks that
• Meniscal degeneration and extrusion contribute to the impairment of load distribution and the increase in compartmental stress.
• Contributions from ligamentous and capsular structures, such as laxity or scarring, alter kinematics and shear forces.
• Neuromuscular dysregulation, which includes quadriceps inhibition, altered proprioception, and compensatory gait patterns, plays a significant role.
• Psychosocial aspects such as activity avoidance, catastrophizing, and fragmented sleep are examples of central sensitization.

Clinically, OA expresses as pain during weight-bearing, morning stiffness, crepitus, reduced range of motion, swelling, and functional limitations. Radiographically, we see joint space narrowing, osteophytes, subchondral sclerosis, and cyst formation. MRI can reveal synovitis, cartilage defects, BMLs, and meniscal pathology. Phenotyping is vital: some patients are inflammation-dominant; others are biomechanically driven; many are mixed. This heterogeneity informs our therapeutic strategy and why PRP, with its pleiotropic signaling capabilities, can offer broad benefit.

What Is Platelet-Rich Plasma? Composition, Preparation, and Biological Rationale

Platelet-rich plasma (PRP) is an autologous concentration of platelets suspended in plasma, obtained by centrifuging a patient’s blood to separate components. The goals are to:

• Enrich platelets above baseline (often targeted 3–6x), delivering growth factors from platelet alpha-granules.
• Keep the number of white blood cells in check to match the target tissue—usually using leukocyte-poor PRP (LP-PRP) for
• Minimize red blood cell (RBC) contamination that can introduce heme and iron, promoting oxidative stress.

Key bioactive molecules include:

• TGF-β: Supports chondrocyte matrix synthesis and modulates inflammation and fibrosis.
• PDGF: Stimulates cell proliferation, chemotaxis, and angiogenic balance.
• VEGF influences microvasculature in joints and must be balanced to avoid pathological angiogenesis.
• IGF-1: Encourages anabolic cartilage activity and proteoglycan synthesis.
• HGF, or hepatocyte growth factor, exhibits anti-inflammatory and antifibrotic properties.
• PF4 (CXCL4) and SDF-1 (CXCL12): Participate in immune modulation and progenitor cell recruitment.
• Exosomes and extracellular vesicles transport signals that may modulate gene expression in chondrocytes and synoviocytes.

The rationale for PRP in knee OA is to counter catabolic signaling, reduce synovial inflammation, and support matrix homeostasis. By providing a concentrated supply of healing substances from the patient’s own body, PRP aims to shift the situation from damage to healing or at least to keep it stable.

PRP Subtypes: Leukocyte-Poor vs. Leukocyte-Rich and Why It Matters

A critical variable in PRP efficacy is leukocyte content:

• Leukocyte-rich PRP (LR-PRP) includes higher levels of neutrophils and monocytes. Neutrophils release proteases and reactive oxygen species that can exacerbate inflammation in the synovial space.
• Leukocyte-poor PRP (LP-PRP) has fewer neutrophils, which helps create a milder immune response

In my practice and in many studies, LP-PRP is the best choice for knee OA because it reduces post-injection flares and improves results. Mononuclear cells (lymphocytes/monocytes) may have reparative signaling roles, but neutrophil-heavy formulations are generally avoided in joints because they can exacerbate inflammation and hinder the healing process in conditions like knee osteoarthritis.

Activation Strategies: Endogenous vs. Exogenous

Platelets can be activated endogenously upon contact with collagen in joint tissue or exogenously using calcium chloride or thrombin. For knee OA, I commonly use non-activated or lightly calcium-activated PRP, allowing physiological release kinetics. Overly aggressive activation can produce a rapid burst of factors without sustained release. The reasoning is to mimic natural platelet degranulation that unfolds over hours to days, potentially aligning better with synovial metabolism.

Centrifugation, Concentration, and Quality Control

PRP preparation must be standardized to ensure reproducibility:

• Spin protocols: A two-step centrifugation (“double spin”) can achieve higher platelet yields while reducing RBCs and neutrophils. The first spin separates plasma; the second concentrates platelets.
• Target concentration: Many protocols aim for 3–6x baseline platelets; higher is not always better. Very high concentrations can surprisingly slow down chondrocyte activity because of too much TGF-β or
• Avoid RBC contamination: Hemolysis and iron catalyze oxidative reactions detrimental to synovium and cartilage.
• Volume and dosing: Typical intra-articular knee doses range from 3–6 mL per injection, often delivered in series (e.g., 1–3 injections spaced 1–4 weeks apart).
• Quality assurance: Document platelet counts, leukocyte levels, and hematocrit post-preparation. Use sterile technique, closed systems where appropriate, and validated kits.

The reasoning behind these steps is to produce a consistent, safe PRP formulation tailored to the joint environment to enhance therapeutic reliability.

Comparative Effectiveness: PRP vs. Corticosteroids vs. HA

Multiple randomized controlled trials and meta-analyses have compared PRP to corticosteroids and hyaluronic acid for knee OA. In many studies:

• Corticosteroids quickly relieve pain (within days to weeks) by strongly reducing inflammation through their effects on NF-κB signaling and However, repeated injections may carry risks of cartilage thinning and structural compromise, which can lead to long-term joint damage and decreased function in patients receiving corticosteroid treatments.
• HA can help make the joint fluid smoother and more flexible, and it has some mild anti-inflammatory effects through CD44 pathways Clinical benefits are variable and often moderate.
• PRP frequently shows superior or more durable improvements in pain and function over 6–12 months, especially in patients with mild-to-moderate OA. Trials report improvements in WOMAC and KOOS scores, with reduced stiffness and enhanced activity levels.

The biological basis for PRP’s comparative advantage resides in its capacity to modulate the joint microenvironment over time, rather than merely alleviating inflammatory symptoms or enhancing lubrication. PRP may promote chondrocyte anabolism, attenuate synoviocyte-derived catabolic signals, and stabilize subchondral cross-talk.

Chondroprotective Potential: Mechanisms and Early Evidence

The term “chondroprotective” suggests the capacity to protect cartilage from further degeneration. PRP’s potential chondroprotection derives from:

• Downregulation of catabolic enzymes (MMP-13, ADAMTS-5) via modulation of IL-1β and TNF-α
• The exposure of chondrocytes to PRP-conditioned media leads to the upregulation of anabolic markers (COL2A1, ACAN).
• The exposure to PRP-conditioned media enhanced synovial homeostasis, reduced inflammatory mediators, and potentially normalized hyaluronan synthesis.
• The treatment has a significant impact on subchondral bone signaling, potentially influencing the Wnt/-catenin pathways and the balance between osteoblasts and osteoclasts.
• Extracellular vesicles are delivered, which influence miRNA-mediated gene regulation and steer towards reparative gene expression profiles.

Although large studies are still ongoing to prove it, several research teams using up-to-date methods are finding signs that PRP can help protect cartilage and slow down disease progression, especially when used early and combined with load management.

Patient Selection: Who Benefits Most from PRP?

Clinical success with PRP hinges on selecting the right patients:

• Ideal candidates are those with mild to moderate knee osteoarthritis (Kellgren-Lawrence grade II–III) who have symptoms and either mechanical or inflammatory issues, but
• Considerations: Age, metabolic health, BMI, alignment, activity level, inflammatory burden, and expectations. Metabolic syndrome and uncontrolled diabetes can dampen response; smoking may impair outcomes.
• Exclusions/relative contraindications: Active infection, coagulopathy, platelet disorders, severe anemia, anticoagulation that cannot be safely paused, metastatic cancer, and pregnancy (case-by-case).
• Medication management: Avoid NSAIDs during the procedure to prevent interference with platelet activation and prostaglandin signaling.

The reasoning is pragmatic: PRP’s reparative signaling needs a receptive biological substrate. End-stage OA with extensive cartilage loss and major malalignment may require surgical solutions.

Protocol Design: Dosing, Timing, and Injection Technique

Protocol nuances matter:

• Dosing schedule: Often 1–3 injections spaced 1–4 weeks apart. Some patients respond to a single injection; others benefit from a series.
• Ultrasound guidance: I favor ultrasound-guided intra-articular injection to ensure precise placement, avoid vascular structures, and minimize discomfort.
• Pre- and post-care involves ensuring proper hydration, avoiding nonsteroidal anti-inflammatory drugs (NSAIDs), engaging in gentle mobility, and following a structured rehabilitation program to align tissue loading with healing signals.
• Pain management: Acetaminophen as needed; ice for comfort; avoidance of corticosteroid co-injection, which may blunt the effects of platelet-rich plasma (PRP) therapy.
• Adjuncts: In select cases, combine with bracing, taping, neuromuscular training, hip and core strengthening, and gait retraining.

The goal is to improve the environment inside the joint, help the body repair itself through movement, and prevent any medications from interfering with

Rehabilitation Integration: The Biomechanical Partnership

PRP is not a standalone solution. I integrate:

• Strengthening the quadriceps and hip abductor muscles can reduce the knee adduction moment and enhance shock absorption.
• I incorporate flexibility routines that target the hamstrings, calves, and hip flexors to balance the sagittal and frontal plane mechanics.
• Proprioceptive and balance training is crucial for reducing perturbation-related stress and enhancing joint stability.
• Gait optimization: Cadence adjustments, stride modifications, and footwear assessment.
• Load management: Activity mapping to reduce peak loads while maintaining mobility; progressive return plans.

The physiological reasoning: Improved neuromuscular control complements PRP’s anti-inflammatory and anabolic effects, reducing shear and compression that perpetuate degeneration.

Measuring Outcomes: Clinical Scales, Imaging, and Biomarkers

To evaluate effectiveness:

• Clinical scales: WOMAC, KOOS, VAS, and patient-specific functional scores.
• Functional tests: Timed Up and Go, a six-minute walk, and stair-climb tests.
• Imaging: Baseline and follow-up X-rays for structure; MRI for cartilage morphology, synovitis, and BMLs.
• Biomarkers: Research tests for CRP, IL-6, COMP, CTX-II, and studying cytokines

We track both symptomatic relief and structural signals to ensure we are not merely masking pain but contributing to healthier joint function.

Safety, Side Effects, and Risk Mitigation

PRP is generally safe when prepared and administered properly:

• Common reactions: Post-injection soreness, transient swelling, mild stiffness, and rare flare-ups.
• Infection risk: Low with sterile technique; prophylactic antibiotics are not typically used.
• Adverse events include rare synovitis exacerbation; avoid use in acute crystal arthropathy; and screen for systemic contraindications.
• Quality control: Document formulations; use validated kits; maintain a chain of sterility.

The autologous nature of PRP reduces immunogenic risks. Education ensures patients anticipate normal post-procedure courses and promptly report unexpected symptoms.

Economics and Accessibility: Value Considerations

While PRP is often paid out-of-pocket, we discuss:

• Cost-benefit: Potentially longer-lasting relief versus repeated steroid or HA injections; reduced need for frequent follow-ups.
• Work productivity and function: Improved mobility and reduced pain can translate into meaningful quality-of-life gains.
• Insurance landscape: Evolving; we provide documentation from evidence-based sources to support medical necessity in select cases.

The reasoning: Transparent conversations build trust and align expectations with the therapy’s value proposition.

Ethical Practice: Transparency, Evidence, and Individualization

I emphasize:

• Informed consent: Discuss benefits, risks, alternatives, and uncertainties.
• Evidence-based framing: Present data clearly, including what is known and not yet proven.
• Individualization: Tailor protocol to phenotype, goals, and comorbidities.
• Follow-up and accountability: Track outcomes, adjust plans, and contribute to practice-based evidence.

Orthobiologic enthusiasm must match rigor in ethical care.

Integration with Multimodal OA Care: Nutrition, Weight, and Behavior

To support PRP outcomes:

• Weight optimization involves reducing knee peak loads and modulating adipokines (leptin, adiponectin), which affect synovial inflammation.
• Nutrition: Protein adequacy, omega-3 fatty acids, and micronutrients supporting collagen synthesis.
• Sleep and stress: Address central sensitization and pain amplification pathways.
• Activity design: Encourage low-impact aerobic work (cycling, swimming) and structured strength programs.

The reasoning: Systemic health influences local joint biology; comprehensive care amplifies the benefits of PRP (platelet-rich plasma) therapy.

Case Reflections: Patterns I See in Practice

In patients with moderate OA, a series of two to three LP-PRP injections over six weeks, coupled with targeted rehab, often yields meaningful improvement by 8–12 weeks, with persistence over several months. Patients with significant misalignment or severe narrowing of the joint space see less benefit; however, those experiencing inflammation often have a strong response, showing clear reductions in swelling and stiffness.

These patterns align with literature showing greater responsiveness in earlier OA stages and point to the value of mechanical correction and phenotyping.

Future Directions: Standardization and Precision Orthobiologics

Leading researchers are working toward:

• Leading researchers are striving to standardize the characterization of PRP, which includes platelet counts, leukocyte profiles, and activation status.
• Biomarker-guided personalization aims to match the PRP subtype to the patient’s phenotype.
• PRP can be combined with other orthobiologics, such as microfragmented adipose tissue and bone marrow concentrate, in carefully controlled trials.
• MRI T2 mapping, dGEMRIC, and quantitative CT are used to monitor long-term structural outcomes.

The future of PRP in OA is precision care—a refined match between therapy and patient biology.

Practical Implementation Checklist for Clinicians

• Use LP-PRP for knee OA to minimize neutrophil-driven synovitis.
• Aim for a platelet concentration that is 3 to 6 times higher than normal; avoid red blood cell (RBC) contamination.
• Consider ultrasound guidance for accurate intra-articular delivery.
• Space 1–3 injections 1–4 weeks apart, depending on phenotype.
• Avoid NSAIDs (non-steroidal anti-inflammatory drugs) around the procedure; educate on post-care.
• Integrate rehabilitation focusing on strength, balance, and gait.
• Track outcomes with WOMAC/KOOS and function tests.
• Document preparation variables for quality assurance.

Addressing Common Questions

• Why not just use corticosteroids? While corticosteroids quickly reduce pain, repeated use may accelerate structural decline. PRP aims to shift the biological balance toward repair and sustained improvement.
• Is HA obsolete? No. HA remains useful in some patients; however, PRP often outperforms HA in durability and magnitude of benefit in many trials, particularly in those with osteoarthritis or joint injuries where enhanced healing is desired.
• Does PRP regrow cartilage? Definitive large-scale evidence of cartilage regrowth is limited; however, signals of chondroprotection and slowed progression are encouraging.
• Will PRP work for severe OA? Less likely. Severe bone-on-bone disease may require surgical solutions; PRP may provide symptom relief but is not a replacement for joint replacement when indicated.

Clinical Pearls and Nuanced Reasoning

• Phenotype matching matters: Inflammation-dominant osteoarthritis (OA) responds differently from purely mechanical OA, which is a type of arthritis caused by wear and tear on the joints.
• Platelet concentration sweet spot: Too low may be ineffective; too high may be inhibitory.
• Leukocyte management: Reducing neutrophils improves tolerability and may enhance intra-articular outcomes, particularly in patients with inflammation-dominant OA, where neutrophil levels can exacerbate symptoms and hinder recovery.
• Mechanotransduction synergy: Proper loading enhances cellular responsiveness to PRP signals.
• Expectations management: Improvements often emerge over weeks, not days; upfront counseling prevents disappointment.

Broader Implications: Orthobiologics as a Bridge in Care

PRP can serve as a bridge for patients seeking to delay surgery while maintaining function or as an adjunct in comprehensive conservative care. Its role is not to eliminate the need for surgery but to provide biologically rational, patient-centered options in the continuum of OA management.

My Commitment as Dr. Jimenez, DC, FNP-APRN

I am committed to delivering modern, evidence-informed orthobiologic care using PRP protocols that reflect current best practices. I collaborate with orthopedic and rheumatology colleagues, physical therapists, and primary care providers to ensure each patient receives individualized, safe, and effective treatment.

References to Current Research Paradigms

In composing this educational post, I prioritize findings from leading researchers whose work employs

• Randomized controlled trials (RCTs)
• Network meta-analyses
• Prospective cohort studies with standardized PRP characterization
• Mechanistic in vitro and ex vivo chondrocyte and synoviocyte models
• Imaging-based outcome quantification

This methodology ensures that clinical recommendations rest on solid evidence, not anecdote.

Practical Takeaways for Patients

• PRP is an autologous, biologically active injection that can reduce knee pain and improve function.
• It is often more durable than corticosteroids or HA in many cases of mild-to-moderate OA.
• Best results occur with proper patient selection, quality-controlled preparation, and structured rehabilitation.
• PRP is not a cure, but it can be a meaningful part of comprehensive OA care.

References

• References include high-quality randomized controlled trials and meta-analyses comparing PRP with corticosteroids and hyaluronic acid in the treatment of knee osteoarthritis.
• Studies have characterized PRP formulations (leukocyte-poor vs. leukocyte-rich) and their intra-articular effects.
• Mechanistic research examines the impact of PRP on chondrocytes, synoviocytes, and inflammatory signaling pathways.
• Imaging-based outcome studies assess cartilage status, synovitis, and bone marrow lesions following PRP treatment.
• There are consensus statements and methodological guidelines for the preparation and reporting of PRP in musculoskeletal medicine.

Note: Specific citations should be tailored to institutional standards and updated regularly with the latest peer-reviewed publications.

Disclaimers

• This post is for information only and not medical advice.
• All individuals must obtain recommendations for their personal situations from their own medical providers.

Summary

I presented a comprehensive educational overview of platelet-rich plasma (PRP) therapy for symptomatic knee osteoarthritis (OA), emphasizing modern, evidence-based findings. Knee OA is a multifactorial disease characterized by cartilage degradation, synovial inflammation, subchondral remodeling, and neuromechanical dysfunction. PRP is a concentrated mixture of platelets and helpful substances from the patient’s own blood that aims to reduce inflammation and promote cartilage cell growth. Compared head-to-head with corticosteroids and hyaluronic acid, PRP frequently demonstrates more durable improvements in pain and function, especially in mild-to-moderate OA. It’s important to improve the PRP process: use a type with fewer white blood cells, aim for the right platelet count, keep red blood cells out, and integrate PRP with rehabilitation focused on strength, balance, gait, and load management to augment mechanotransduction and functional recovery. Emerging research suggests potential chondroprotective effects, though long-term disease-modifying evidence continues to evolve. Patient selection matters; severe malalignment or end-stage OA may limit the effectiveness of PRP. Safety is favorable with proper sterility and quality control. Ethically, clinicians should provide transparent, individualized care grounded in high-quality research. PRP can serve as a bridge or adjunct within comprehensive OA management—offering a biologically rational option for patients seeking sustained improvement.

Conclusion

PRP is a promising orthobiologic therapy for knee OA when aligned with evidence-based protocols and individualized care. By addressing the joint’s biochemical and biomechanical environment, PRP can provide meaningful relief and functional gains beyond what corticosteroids or HA often offer. The future of PRP lies in standardization, precision formulation, and ongoing comparative effectiveness research. With careful patient selection, protocol rigor, and integrated rehabilitation, PRP can play a central role in contemporary OA care.

Key Insights

• PRP leverages autologous growth factors and cytokines to modulate synovial and cartilage biology, which can enhance healing and reduce pain in patients with osteoarthritis.
• Leukocyte-poor PRP is generally preferred for intra-articular knee injections to minimize inflammatory flare.
• Comparative studies often show PRP’s superior durability versus corticosteroids and HA in mild-to-moderate OA.
• Protocol standardization (concentration, activation, and guidance) and rehabilitation integration are decisive for outcomes, as they ensure that the treatment is effective and tailored to individual patient needs.
• Early signals of chondroprotection warrant cautious optimism and continued research to confirm disease-modifying potential.